← Back to Search

Other

Serial PRP injections for Hoarseness

N/A
Waitlist Available
Led By Michael Johns, MD
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights

Summary

This trial will test whether four monthly injections of platelet-rich plasma can improve voice quality in people with vocal fold atrophy, scarring, or sulcus vocalis.

Eligible Conditions
  • Vocal Fold Scar
  • Presbylarynx
  • Hoarseness
  • Laryngeal Atrophy
  • Vocal Cord Atrophy
  • Presbylarynges
  • Sulcus Vocalis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Emergent Adverse Events as assessed by FDA/CBER Adverse Event Severity Grading Scale
Secondary outcome measures
Objective Vocal Quality as assessed by experts using the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) instrument
Diagnostic Imaging
Voice-Related Quality of Life as assessed by Voice Handicap Index-10 (VHI-10) and Vocal Fatigue Index (VFI)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Serial PRP injectionsExperimental Treatment1 Intervention
This arm will receive experimental intervention of serial monthly platelet-rich plasma (PRP) injections to a unilateral vocal fold mucosa for a total of 4 injections.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Serial PRP injections
2020
N/A
~20

Find a Location

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
919 Previous Clinical Trials
1,611,427 Total Patients Enrolled
Michael Johns, MDPrincipal InvestigatorUniversity of Southern California
1 Previous Clinical Trials
18 Total Patients Enrolled
~3 spots leftby Jul 2025